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Abstract
Background: The immune modulating properties of statins may benefit smokers with asthma. We tested the
hypothesis that short-term treatment with atorvastatin improves lung function or indices of asthma control in
smokers with asthma.
Methods: Seventy one smokers with mild to moderate asthma were recruited to a randomized double-blind
parallel group trial comparing treatment with atorvastatin (40 mg per day) versus placebo for 4 weeks. After
4 weeks treatment inhaled beclometasone (400 μg per day) was added to both treatment arms for a further
4 weeks. The primary outcome was morning peak expiratory flow after 4 weeks treatment. Secondary outcome
measures included indices of asthma control and airway inflammation.
Results: At 4 weeks, there was no improvement in the atorvastatin group compared to the placebo group in
morning peak expiratory flow [-10.67 L/min, 95% CI -38.70 to 17.37, p = 0.449], but there was an improvement
with atorvastatin in asthma quality of life score [0.52, 95% CI 0.17 to 0.87 p = 0.005]. There was no significant
improvement with atorvastatin and inhaled beclometasone compared to inhaled beclometasone alone in outcome
measures at 8 weeks.
Conclusions: Short-term treatment with atorvastatin does not alter lung function but may improve asthma quality
of life in smokers with mild to moderate asthma.
Trial Registration: Clinicaltrials.gov identifier: NCT00463827
Background
Smokers with asthma have poor symptom control,
accelerated decline in lung function and an attenuated
response to inhaled corticosteroids compared to non-
smokers with asthma[1-4]. Optimum medical therapy
for smokers with asthma has not been established.
There is an unmet need for alternative or additional
drugs for smokers with asthma who are unable to stop
smoking.
In addition to reducing cholesterol biosynthesis by
inhibiting 3-hydroxy-3-methylgluteryl coenzyme A
(HMG-CoA) reductase, statins have pleiotropic anti-
inflammatory effects[5] that may be beneficial in the
treatment of chronic inflammatory diseases[5,6]. Precli-
nical in vitro and in vivo studies, including experimental
models of allergic lung inflammation[7,8], have shown
that statins reduce components of airway inflammation
potentially relevant to the pathogenesis of asthma.
Despite preliminary data showing an absence of clinical
benefit with short-term statin therapy on asthma symp-
toms or lung function in non-smokers with asthma
[9-11], there is indirect evidence to suggest that statins
may show efficacy in patients with asthma who smoke.
First, simvastatin inhibits lung parenchymal destruction,
peribronchial and perivascular inflammatory cell infil-
trate and leads to a reduction in levels of matrix metal-
loproteinase-9 in a rat model of smoking related lung
disease[12] and reduces airway inflammation and
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mice[13]. Second, statins enhance corticosteroid sensi-
tivity in asthma[14,15], possibly by restoring histone
deacetylase (HDAC) activity[16], which is reduced by
cigarette smoking[17]. Thirdly, retrospective or case
cohort studies have shown statin use is associated with
a reduced decline in lung function in cigarette smokers
[18] and reduced exacerbation rates, hospital admission
and mortality in patients with COPD[19]. Taken
together, this evidence suggests that statin treatment
may improve asthma control in smokers with asthma.
This study aimed to test the hypothesis that short term
treatment with atorvastatin, either alone or in addition
to low dose inhaled corticosteroid improves lung func-
tion or other indices of asthma control and/or airway
inflammation in smokers with asthma. Atorvastatin was
chosen because of its favourable in vitro and in vivo
anti-inflammatory properties [20-22] and evidence of
clinical benefit at the dose of 40 mg daily in rheumatoid
arthritis [21].
Methods
Study subjects
Cigarette smokers with chronic asthma symptoms of
more than one year duration, aged 18 to 60 years were
eligible to take part. Participants were regular smokers
with a history of 5 pack years or more. Patients were
recruited from general practice, hospital clinics and
research databases. Smoking cessation advice was
offered at the study screening visit and eligible subjects
who were not willing to quit were enrolled. Patients
were excluded if they were already taking a statin or
medications known to interact with statins such as anti-
fungal agents, macrolide antibiotics, cyclosporin, gemfi-
brozil, verapamil and amiodarone. All subjects
demonstrated reversibility in FEV1 following salbutamol
of ≥12% and ≥200 ml or PC20 ≤ 8m g / m lo r≥ 20%
variability in peak expiratory flow (PEF)[23]. The West
Glasgow Research Ethics Committee approved the study
and all patients gave written informed consent.
Study design
The aim of the study was to test the hypothesis that short-
term treatment with atorvastatin improves lung function
or indices of asthma control or airway inflammation in
smokers with asthma. Patients had been free of exacerba-
tion and lower respiratory tract infection for a minimum
period of 6 weeks prior to randomization. Where relevant,
inhaled corticosteroid (ICS) and long-acting bronchodila-
tor (LABA) treatment were weaned over a 4-10 week per-
iod. On completion of a two-week run in period free from
ICS and LABA, a baseline visit was performed. Subjects
recorded their PEF and asthma symptoms twice daily
throughout the study. Randomization was conducted via
an interactive telephone service (IVRS) in randomized
blocks of length four. Patients were assigned to eight
weeks of atorvastatin 40 mg daily or a matched placebo.
After four weeks inhaled beclometasone (Clenil
® Modu-
lite
® 200 μg twice daily) was also commenced in both
randomized groups. Treatment with short-acting b-2 ago-
nist was allowed throughout the study. At baseline, 4 and
8 week visits, electronic PEF data were downloaded and
spirometry performed. At these visits patients completed a
validated asthma control questionnaire (ACQ) and asthma
quality of life questionnaire (AQLQ); induced sputum was
performed and exhaled nitric oxide was measured. At
baseline and 8 weeks, blood samples were taken for immu-
nological tests, lipids and liver transaminases.
Measurements
PEF was recorded using Piko-1 electronic peak flow
meters (nSpire Hertford UK) and symptoms were
recorded in a validated diary card[24]. ACQ[25] and
AQLQ [total and individual domains][26] results were
also recorded. The total AQLQ score is the mean of all
32 responses and the individual domain scores are the
means of the items in those domains. A change in score
of 0.5 is the smallest change that is considered clinically
important. Exhaled nitric oxide (NO) levels were mea-
sured at 50 ml/s in concordance with standardised
guidelines[27] (Niox Flex, Aerocrine, Sweden). Spirome-
try was performed to American Thoracic Society guide-
lines. Exhaled carbon monoxide levels were measured
by hand held Smokerlyser. (Bedford scientific, UK). Air-
way hyper-responsiveness was measured by Cockcroft’s
methacholine challenge test with concentrations from
0.03 mg/ml to 16 mg/ml[28]. Blood samples were pro-
cessed by local accredited laboratories for urea and elec-
trolytes, liver transaminases, thyroid function, creatinine
kinase levels and lipid profile; haematological testing
(full blood count), and total IgE and specific IgE to cat,
house dust mite and grass. Total IgE levels >120 IU/ml
w a sc o n s i d e r e de l e v a t e da n ds p e c i f i cI g El e v e l s> 0 . 3 5
AU/ml was used to define atopic status. Sputum induc-
tion was performed as previously described[29], using a
low concentration of DTT (0.003%) to disperse cells
without undue effects on mediator measurements. Spu-
tum supernatant fluid was analysed for leukotriene (LT)
B4 and myeloperoxidase (MPO) using enzyme immu-
noassay (EIA) (LTB4 from R&D Systems, Abingdon, UK,
MPO from Cambridge Bioscience, Cambridge, UK.), and
interleukin (IL)-2, 4, 6, 8, 10 and tumor necrosis factor
(TNF)-a using a Luminex microbead fluorescence kit
(Biosource, Invitrogen, Paisley, UK). Serum was analysed
for high sensitivity (hs)-CRP by EIA (R & D Systems)
and sICAM-1, E-selectin, P-selectin, IL-2, 4, 6, 8, 10 and
TNF-a using a multiplex fluorescence bead kit (sICAM-
1, E-selectin and P-selectin from Merck Chemicals,
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source). Current smoking was confirmed by serum coti-
nine measurement (Cozart, Oxfordshire, UK).
Treatment compliance was assessed by tablet count and
inhaler weight. Adverse event information was reviewed
at each study visit.
Analysis
Baseline characteristics were described by number and
percentage of patients for categorical variables and
mean (SD) or median and inter-quartile range for nor-
mally distributed or skewed continuous variables respec-
tively. The full analysis set was defined as all
randomized subjects with at least one post-baseline
assessment of PEF (primary endpoint). The primary
endpoint was calculated as the mean of the morning
PEF measurements from the Piko-1 electronic peak flow
meter recordings during the seven days immediately
preceding each study visit. If fewer than three days of
data were recorded within that period, patient diary
entries for morning PEF were substituted in place of the
missing values. The mean was then calculated if there
were at least three days of data available, otherwise the
response was taken to be missing. Response to atorvas-
tatin on lung function, diary data, induced sputum,
mediator levels and exhaled nitric oxide versus placebo
was assessed by analysis of covariance, where the
r e s p o n s ew a sc h a n g ef r o mb a s e l i n ea n dt h eb a s e l i n e
value was the covariate. All data were analysed using
SAS version 9 (SAS Institute, Cary, NC). A sample size
of 68 was calculated to have 80% power to detect a
mean difference of 25 L/min in change from baseline to
four weeks in morning PEF, the primary endpoint[30],
assuming a standard deviation of changes of 36 L/min,
using a two sample t-test with a 5% two-sided signifi-
cance level. Recruitment of 74 patients was planned to
ensure that 68 patients completed the study.
Results
Recruitment and baseline characteristics
Of the 286 subjects contacted, 131 volunteers were
consented and 71 were randomized to either the ator-
vastatin treatment group (n = 36) or the placebo group
(n = 35) (Figure 1). Baseline demographic and clinical
characteristics of patients are listed in Tables 1 and 2.
The two groups were well balanced with respect to
these characteristics.
Changes in clinical outcomes
Changes in clinical outcomes after atorvastatin treatment
are listed in Table 2 and illustrated in Figure 2. At 4
weeks, the change in mean morning PEF, as compared
with baseline, did not differ substantially between the
atorvastatin and placebo treatment periods [mean
Figure 1 Flow of patients through study.
Table 1 Demographics and clinical baseline
characteristics
Atorvastatin
(n = 36)
†
Placebo
(n = 32)
†
Age, years 40.4
(34.8,45.5)
43.0
(38.1,52.0)
Male sex, n (%) 15 (41.7%) 15 (46.9%)
Smoking history (pack years) 24 (14,34) 21 (10,30)
Duration of asthma symptoms, years 24.0
(14.5,32.5)
19.5 (12.5,
38.5)
Atopic, n (%) 18 (54.5%) 21 (67.7%)
Total IgE (IU/ml) 82 (19,192) 197 (76,517)
Use of inhaled corticosteroid at
screening, n (%)
19 (52.8%) 16 (50.0%)
Equivalent beclometasone dose at
screening, μg
100 (0,400) 200 (0,800)
Use of LABA at screening, n (%) 8 (22.2%) 14 (43.8%)
Pre-bronchodilator FEV1 % predicted 84 (71,98) 79 (65,92)
FEV1 % reversibility 11 (6,16) 12 (8,19)
Serum cotinine (ng/mL) 85 (78,90) 82 (79,94)
Definition of abbreviations: FEV1, Forced Expiratory Volume in one second;
LABA, long-acting beta2-agonist.
Data represented as median (IQR) unless specified.
†Number of randomized subjects with at least one post-baseline assessment
of PEF.
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Page 3 of 10difference -10.67 L/min, 95% CI -38.70 to 17.37, p =
0.449]. There was an improvement in the atorvastatin
group compared to the placebo group at 4 weeks in the
ACQ score [-0.37, 95% CI -0.67 to -0.07, p = 0.016] and
AQLQ total score [0.52, 95% CI 0.17 to 0.87 p = 0.005]
as well as AQLQ symptoms domain [0.63, 95% CI 0.18 to
1.09 P = 0.007], activity limitations domain [0.40, 95% CI
0.10 to 0.71 P = 0.010] and emotional functions domain
[0.60, 95% CI 0.10 to 1.09) P = 0.019]. At 8 weeks there
was no significant improvement with atorvastatin and
inhaled beclometasone compared to inhaled beclometa-
sone alone in primary or exploratory outcome measures.
Changes in inflammatory biomarkers
After 4 and 8 weeks, the total cell count and differential
cell counts in induced sputum were similar for
Table 2 Clinical outcomes after atorvastatin treatment or placebo
Variables Baseline 4 weeks †Treatment
difference,
atorvastatin
minus
placebo
(95% CI)
8 weeks †Treatment
difference,
atorvastatin
minus
placebo
(95% CI)
Atorvastatin
(n = 36)
Placebo
(n = 32)
Atorvastatin
(n = 34)
Placebo
(n = 30)
Atorvastatin
& ICS
(n = 33)
Placebo
& ICS
(n = 27)
Morning PEF L/min 381.33
(138.79)
348.99
(116.49)
376.39
(141.63)
357.65
(121.38)
-10.67
(-38.70, 17.37)
p = 0.449
390.51
(123.38)
354.64
(123.70)
10.68
(-20.29, 41.65)
p = 0.492
Evening PEF L/min 391.9
(137.1)
375.8
(118.4)
384.8
(137.1)
367.4
(117.2)
4.95
(-18.61, 28.51)
p = 0.676
400.0
(140.1)
368.3
(130.5)
25.03
(-2.04, 52.11)
p = 0.069
FEV1 pre-salbutamol, L 2.76
(0.91)
2.51
(0.76)
2.79
(0.83)
2.59
(0.74)
-0.01
(-0.13, 0.11)
p = 0.872
2.80
(0.89)
2.63
(0.76)
0.03
(-0.10, 0.16)
p = 0.651
FEV1 post-salbutamol, L 3.08
(0.94)
2.88
(0.75)
3.02
(0.88)
2.89
(0.75)
-0.03
(-0.13, 0.07)
p = 0.492
3.02
(0.90)
2.93
(0.74)
-0.02
(-0.12, 0.07)
p = 0.642
PC20 methacholine
geometric mean, mg/ml
3.29
(4.03)
2.15
(3.34)
4.12
(4.86)
2.93
(5.0)
1.36
(-1.29, 4.01)
p = 0.307
5.31
(6.2)
2.31
(4.0)
1.37
(-0.65, 3.40)
p = 0.179
ACQ Score
[6 questions]
1.86
(1.02)
1.86
(0.82)
1.42
(0.68)
1.91
(1.10)
-0.48
(-0.84,-0.12)
p = 0.009
1.29
(0.93)
1.64
(1.10)
-0.37
(-0.8,0.07)
p = 0.096
ACQ score
[7 questions]
1.88
(1.00)
1.96
(0.79)
1.50
(0.67)
1.90
(0.90)
-0.37
(-0.67, -0.07)
p = 0.016
1.38
(0.93)
1.77
(1.00)
-0.35
(-0.74, 0.04)
p = 0.081
AQLQ
Total score
5.36
(1.05)
5.14
(1.14)
5.71
(0.83)
5.04
(1.30)
0.52
(0.17, 0.87)
p = 0.005
5.79
(1.02)
5.27
(1.34)
0.37
(-0.02, 0.76)
p = 0.063
AQLQ Symptoms Domain 4.96
(1.08)
4.82
(1.20)
5.46
(0.90)
4.74
(1.39)
0.63
(0.18, 1.09)
p = 0.007
5.67
(4.96,6.34)
4.88
(3.91,6.5)
0.42
(-0.05, 0.89)
p = 0.082
AQLQ Activity Limitations
Domain
5.84
(1.06)
5.52
(1.15)
5.99
(0.90)
5.36
(1.25)
0.40
(0.10, 0.71)
p = 0.010
6.08
(0.97)
5.58
(1.29)
0.31
(-0.01, 0.63)
p = 0.061
AQLQ Emotional
Functions Domain
5.51
(1.36)
5.10
(1.35)
5.90
(1.19)
5.02
(1.62)
0.60
(0.10, 1.09)
p = 0.019
5.87
(1.39)
5.30
(1.62)
0.24
(-0.26, 0.74)
p = 0.335
AQLQ Environmental
Stimuli Domain
5.10
(1.30)
5.09
(1.33)
5.41
(1.18)
5.07
(1.44)
0.34
(-0.09, 0.77)
p = 0.123
5.71
(1.15)
5.13
(1.47)
0.55
(0.07, 1.03)
p = 0.026
Reliever inhaler puffs per
24 hrs
3.19
(2.55)
2.94
(2.93)
2.58
(2.67)
3.97
(5.45)
-0.66
(-1.69, 0.37)
p = 0.205
2. 13
(2.63)
1.99
(2.33)
-0.12
(-1.35, 1.11)
p = 0.841
Abbreviations: ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; PEF, peak expiratory flow rate; FEV1, forced expiratory volume in
one second; Data represented as mean (SD) unless otherwise indicated.
†Treatment difference from analysis of covariance, analysing change from baseline and adjusting for baseline value.
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serum concentrations of inflammatory cytokines and
mediators were similar after atorvastatin compared to
after placebo treatment at the 4 week and 8 week time
points (Table 3 and data not shown). There was no sig-
nificant change in FENO after atorvastatin compared to
placebo (data not shown).
Change in biochemical markers
The biochemical effects of atorvastatin therapy were
reflected in significant reduction in concentration of
serum lipids; cholesterol [-1.55, 95% CI -1.88 to -1.23
P < 0.0001], LDL-cholesterol [-1.50, 95% CI -1.88 to
-1.13 P < 0.0001] and triglyceride [-0.49, 95% CI -0.87,
-0.11 P = 0.013] (Table 4).
Adverse events
No suspected unexpected serious adverse reactions
(SUSARs) were recorded. Adverse events (AEs) were
similar between treatment groups. Two serious adverse
events occurred, one in each group and neither related
to study drug. For adverse events greater than 5% in fre-
quency, the only severe AE was back pain in 3 (8.3%)
subjects in the atorvastatin group versus 0 in the pla-
cebo group. Moderate side effects were more frequent
in the atorvastatin group: oral candidiasis (2 subjects
versus 0), neck pain (2 versus 0) and asthma worsening
(2 versus 1).
Compliance
Compliance assessed by inhaler weight and tablet count
was greater than 90% in both groups. The marked
reduction in LDL-cholesterol in the group receiving
atorvastatin (Table 4) provides further evidence of com-
pliance. The weights of the returned inhalers indicate
similar compliance with the inhaled beclometasone
treatment.
Discussion
In this randomized controlled study we found no
improvement in the atorvastatin group compared to the
placebo group in lung function in smokers with mild to
moderate asthma, whereas there was an improvement in
ACQ and AQLQ scores at 4 weeks. Atorvastatin treat-
ment had no anti-inflammatory effects on induced spu-
tum cell counts or on selected sputum or circulating
blood mediator levels.
Three previous randomized controlled crossover clini-
cal trials reported an absence of clinical benefit with
short-term statin therapy on asthma symptoms or lung
function in non-smokers with asthma[9-11]. The lack of
improvement in PEF, FEV1 or airway responsiveness to
methacholine in asthmatic smokers following atorvasta-
tin supports the conclusions of these earlier studies that
statins do not have a short-term beneficial effect on
lung function in asthma irrespective of smoking status.
In addition to poor symptom control, smokers with
asthma have worse asthma-specific quality of life scores
[31]. The AQLQ is a well validated score of subjective
well being and improving this index is an important
goal of asthma management[32]. As one of a number of
outcome measure we found a mean between-group dif-
f e r e n c ei nc h a n g ef r o mb a s e l i n ei nA Q L Qs c o r eo f0 . 5 2
at 4 weeks, which is just greater than the minimal clini-
cally significant change in score of 0.5[33]. The
Figure 2 Change from baseline for both treatment groups in
(a) morning PEF [L/min], (b) ACQ score, (c) AQLQ total score at
4 weeks. P values are for comparisons of the mean change from
baseline between the two treatments.
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Variables Baseline 4 weeks Treatment difference,
atorvastatin minus
placebo (95% CI)
8 weeks Treatment difference,
atorvastatin minus
placebo (95% CI)
Atorvastatin
(n = 35)
Placebo
(n = 32)
Atorvastatin
(n = 31)
Placebo
(n = 29)
Atorvastatin & ICS
(n = 32)
Placebo & ICS
(n = 24)
Sputum differential
cell count &
proportion (%)
Total cell count (×10
4) 651.5
(547.0, 890.5)
620.8
(543.2, 758.8)
628.5
(533.5, 921.5)
602.0
(512.0, 791.0)
43.0
(-75.2, 161.1)
p = 0.469
607.8
(517.0, 785.5)
658.5
(563.2, 860.2)
-81.6
(-177.2,14.0)
p = 0.093
Macrophage (×10
4)
Macrophage %
154.5
(111.5, 263.0)
38.4
(29.6, 61.3)
179.8
(87.2, 242.2)
45.1
(31.8, 58.7)
159.5
(132.0, 221.0)
45.5
(31.5, 58.9)
142.5
(81.0, 220.0)
38.5
(24.6, 54.6)
16.9
(-27.5, 61.3)
p = 0.450
4.8
(-5.9, 15.5)
p = 0.374
173.2
(126.2, 247.2)
41.4
(34.1, 54.9)
174.2
(122.8, 250.5)
44.2
(32.3, 59.0)
-3.0
(-47.6, 41.6)
p = 0.893
-0.5
(-9.6, 8.6)
p = 0.913
Neutrophil (×10
4)
Neutrophil %
131.0
(76.0, 232.5)
37.8
(18.3, 54.2)
122.8
(56.2, 201.2
29.9
(15.0, 49.1)
136.5
(61.0, 233.5)
33.6
(18.2, 55.8)
99.0
(69.5, 299.5)
31.5
(17.6, 63.2)
-19.2
(-72.0, 33.6)
p = 0.470
-4.7
(-15.7, 6.4)
p = 0.401
151.8
(80.5, 211.5)
38.3
(23.0, 52.8)
149.0
(78.2, 229.0)
34.9
(20.7, 49.5)
-8.0
(-49.4, 33.4)
p = 0.700
2.1
(-8.0, 12.1)
p = 0.680
Eosinophil (×10
4)
Eosinophil %
3.0
(0.5, 7.5)
0.6
(0.1, 2.4)
1.5
(0.0, 5.8)
0.4
(0.0, 1.4)
1.5
(0.0, 4.5)
0.4
(0.0, 1.0)
1.5
(0.0, 3.5)
0.3
(0.0, 1.2)
-3.2 (-8.6, 2.3)
p = 0.253
-1.0
(-2.3, 0.3)
p = 0.138
1.3
(0.3, 5.5)
0.4
(0.1, 1.1)
0.8
(0, 2.5)
0.2
(0, 0.6)
0.4
(-1.6,2.5)
p = 0.677
0.1
(-0.4, 0.5)
p = 0.798
Lymphocyte (×10
4)
Lymphocyte %
1.5
(0.0, 3.0)
0.3
(0.0, 0.7)
0.8
(0.0, 2.8)
0.2
(0.0, 0.7)
0.5
(0.0, 3)
0.1
(0.0, 0.7)
0.5
(0.0, 1.5)
0.1
(0.0, 0.5)
0.8
(-0.2, 1.9)
p = 0.125
0.1
(-0.2, 0.4)
p = 0.425
0.8
(0.0, 2.0)
0.2
(0.0, 0.7)
1.3
(0.0, 2.5)
0.4
(0.0, 0.6)
-0.1
(-1.3, 1.1)
p = 0.865
0.1
(-0.3, 0.4)
p = 0.757
Bronchial epithelial cell (×10
4)
Br. epithelial cell %
44.0
(26.0, 90.5)
11.5
(5.9, 26.0)
49.5
(29.0, 117.0)
12.3
(7.8, 29.2)
33.0
(18.0, 78.0)
8.4
(5.9, 17.8)
37.5
(24.0, 89.5)
9.2
(5.6, 24.8)
20.6
(-9.6, 50.9)
p = 0.177
1.6
(-5.9, 9.0)
p = 0.680
40.0
(28.0, 75.8)
11.2
(6.8, 22.2)
57.8
(39.5, 92.8)
13.3
(9.2, 22.5)
-10.3
(-32.7, 12.1)
p = 0.361
-1.3
(-7.7, 5.1)
p = 0.679
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Sputum mediators
Leukotriene B4
(pg/ml)
103.1
(79.7, 185.4)
172.0
(106.0, 422.4)
98.4
(56.9, 215.2)
175.2
(77.0, 336.0)
-49.4
(-205.1, 106.4)
p = 0.528
104.9
(41.9, 151.5)
159.0
(81.0, 520.2)
-231.4
(-589.5, 126.6)
p = 0.200
MPO
(ng/mL)
16.5
(6.4, 39.6)
27.0
(10.6, 40.6)
16.4
(9.0, 30.5)
20.6
(10.6, 34.1)
-16.5
(-48.0, 15.0)
p = 0.298
14.8
(6.4, 34.5)
28.1
(8.9, 68.8)
-111.2
(-264.8, 42.5)
p = 0.152
Interleukin-6 (pg/ml) 139.5
(33.9, 276.5)
220.4
(70.0, 498.5)
109.3
(33.9, 351.5)
144.4
(40.3, 391.6)
-5.6
(-254.1, 243.0)
p = 0.964
147.2
(35.9, 223.0)
122.0
(34.1, 518.6)
-22.5
(-247.3, 202.3)
p = 0.841
Interleukin-8 (pg/ml) 813.1
(238.8, 3000.0)
3000.0
(426.1, 3000.0)
408.5
(179.7, 3000.0)
1686.0
(353.2, 3000.0)
-453.4
(-1071.9, 165.1)
p = 0.127
386.5
(180.7, 3000.0)
541.5
(239.4, 3000.0)
172.3
(-600.8,945.4)
p = 0.656
Interleukin-10 (pg/ml) 13.6
(1.0, 126.9)
13.0
(1.2, 80.9)
1.8
(0.3, 105.3)
15.4
(0.8, 53.4)
27.5
(-53.2, 108.2)
p = 0.497
6.1
(0.7, 72.6)
4.6
(0.7, 62.9)
-4.2
(-132.8, 124.5)
p = 0.948
Serum biomarkers
hs-CRP (mg/L) 2.8
(1.6, 4.0)
3.6
(1.5, 6.9)
2.6
(1.6, 5.0)
2.8
(1.4, 5.6)
0.9
(-4.1, 5.9)
p = 0.718
1.9
(1.0, 4.1)
2.1
(1.0, 5.1)
0.6
(-2.8, 3.9)
p = 0.731
Interleukin-6 (pg/ml) 2.0
(0.2, 4.1)
2.6
(0.2, 30.0)
2.7
(0.2, 11.0)
1.8
(0.2, 26.0)
-9.1
(-20.8, 2.7)
p = 0.127
0.4
(0.2, 8.8)
3.1
(0.2, 21.2)
16.7
(-29.5, 62.8)
p = 0.472
Abbreviations: CRP, C-reactive protein; MPO, myeloperoxisade; Mediator levels pg/ml unless otherwise indicated. Data represented as median (IQR) unless otherwise indicated.
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0individual AQLQ domains for symptoms and emotions
also crossed this threshold. The improvement in AQLQ
score with atorvastatin is comparable to that reported
with long-acting b2 agonist therapy[34] and with leuko-
triene receptor antagonist therapy in non-smokers with
asthma[35]. The non-significant mean improvement in
ACQ score of -0.37 did not reach the minimum impor-
tant reduction threshold of -0.5[36]. Improvements in
subject-centered outcomes with interventions in asthma
are usually associated with better lung function,
although this is not always the case. For example, clini-
cally important improvements in the AQLQ score were
observed in a trial comparing different formulations of
inhaled beclometasone[37] and in a double-blind sham-
controlled trial of bronchial thermoplasty[38] while in
both studies conventional clinical indices of lung func-
tion and asthma control were similar.
Statins restore corticosteroid sensitivity in patients
with asthma[14,15], possibly by restoring HDAC activity
[16] or by increased induction of indoleamine 2, 3-diox-
ygense resulting in increased secretion of the anti-
inflammatory cytokine IL-10[15]. Statins also inhibit IL-
17 expression and secretion from human Th17 cells[39],
which have been implicated in causing corticosteroid
resistance[40]. Based on these studies we wished to
determine whether atorvastatin might restore sensitivity
to corticosteroids and had hoped to observe a beneficial
effect of atorvastatin and inhaled beclometasone com-
pared to inhaled beclometasone alone, but found no
significant effect in outcome measures at the 8 week
time point. It is possible that 4 weeks was not long
enough to demonstrate a synergistic effect, although in
previous studies a 4 week treatment period was long
enough to show the potentiating effects of low dose
theophylline on corticosteroid sensitivity in smokers
with asthma[41].
Statins have pleiotropic properties including anti-
inflammatory and immuno-modulatory effects [5] that
may be beneficial in the treatment of chronic inflamma-
tory airway diseases[6]. The anti-inflammatory effects of
statins are thought to be mediated by inhibition of the
isoprenylation of small G-protein signalling molecules
and by prevention of lipid raft formation, pathways
involved in cell proliferation, activation and oxidative
stress. Statins have immune modulating properties in
animal models of allergic asthma[7,8] and COPD[12,13].
In our study, a limited investigation of circulating and
airway inflammatory cells and mediators failed to show
any effects of atorvastatin therapy on inflammatory bio-
markers including CRP, despite good drug compliance
and significant reduction of serum lipid markers.
There are several limitations of the study. Firstly, if
fewer than three days of data were recorded during the
seven days immediately preceding each study visit,
patient diary entries for morning PEF were substituted
in place of the missing value, which raises the possibility
of increased variability in PEF measurements. However
this procedure was performed in a minority of PEF
Table 4 Serum biochemical outcomes after atorvastatin treatment or placebo
Variables Baseline 8 weeks Treatment difference,
atorvastatin minus
placebo (95% CI)
Atorvastatin
(n = 35)
Placebo
(n = 32)
Atorvastatin & ICS
(n = 32)
Placebo &ICS
(n = 25)
Total cholesterol
(mmol/l)
5.15
(0.89)
5.67
(1.12)
3.62
(0.76)
5.34
(0.90)
-1.55
(-1.88, -1.23)
P < 0.0001
Triglycerides
(mmol/l)
1.59
(0.87)
2.18
(1.41)
1.02
(0.35)
1.74
(1.29)
-0.49
(-0.87, -0.11)
P = 0.013
LDL-cholesterol
(mmol/l)
3.19
(0.82)
3.49
(0.99)
1.89
(0.62)
3.46
(0.87)
-1.50
(-1.88, -1.13)
P < 0.0001
HDL-cholesterol
(mmol/l)
1.24
(0.35)
1.26
(0.31)
1.29
(0.35)
1.23
(0.27)
0.03
(-0.06, 0.13)
p = 0.497
Alkaline phosphatase
(IU/l)
83.33
(31.36)
75.16
(21.04)
98.62
(91.26)
77.16
(19.58)
5.94
(-15.67, 27.54)
p = 0.584
ALT
(IU/l)
17.58
(9.27)
22.50
(11.88)
22.00
(14.37)
24.04
(11.70)
3.67
(-1.84, 9.18)
p = 0.188
Abbreviations: ALT, alanine aminotransferase.
Data represented as mean (SD).
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Page 8 of 10measurements used in the analysis and is unlikely to
have influenced the PEF result. Secondly, while ques-
t i o n n a i r es c o r e sw e r en o ts i g n i f i c a n t l yd i f f e r e n ta tb a s e -
line, it is possible that the slight difference in the
proportion of participants taking LABA prior to screen-
ing may have had an effect on subsequent measure-
ments of asthma control. The short duration of
treatment with atorvastatin may have missed an effect
on clinical or inflammatory outcomes. Future studies
should assess whether treatment with statins influence
outcome measures such as exacerbation rate and decline
in lung function in smokers with asthma and in indivi-
duals with more severe disease. Statins have an inhibi-
tory effect on human airway smooth muscle cell
proliferation[42] and indices of airway remodelling
[43-45]. It is possible that the administration of atorvas-
tatin therapy for a longer duration of time may improve
outcome measures of airway remodelling in asthma’
Conclusion
In conclusion, short-term treatment with atorvastatin
does not improve lung function in smokers with mild to
moderate asthma, but may improve asthma quality of
life. Further trials using statins in asthmatic smokers are
indicated.
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